Abstract:Abstract Background Five-aminosalicylates (5ASAs) promote & maintain remission in people with ulcerative colitis (UC) and are administered orally or rectally, with combination therapy (oral + rectal) more effective than oral monotherapy, especially when treating flares1. 5ASAs may be perceived as out-dated and thus neglected. With increasing UC incidence & prevalence in emerging nations, understanding real-world 5ASA use and value is vital. Methods Crohn’s Colitis Care is a cloud-based electronic medical record used in Australasia. Data feed into a de-identified clinical quality registry (CQR), which was interrogated in September 2023. People with UC under active care (encounter within 14 months) were included. Results Of the 2,522 eligible people, 78.4% resided in Australia & 21.6% in New Zealand (NZ). The median age was 41 years (IQR 31-56), with an even gender distribution (50.3% female). Median disease duration was 9 years (IQR 4.4-16.7). Median duration of follow up was 25.9 months (IQR 13.0-41.4). Overall, 39.2% (n=989) had no documentation of 5ASA therapy (42.0% in Australia, 28.9% in NZ; Table 1). In those with documented 5ASA therapy (60.8%, n=1,534), the average 5ASA treatment duration was 9 years (IQR 4.4-16.7) and women were more likely to receive rectal administration than men (p<0.05). In those who ceased 5-ASA therapy, 782 (44.8%) had a reason documented, with the most common being medication rationalisation and/or deep remission (40.0%) (Figure 1), usually due to up-titration to a more advanced therapy. A total of 608 (39.6%) were recorded as already receiving additional IBD therapy at CQR entry (immunomodulators [IMs]/biologics/small molecules). Of those receiving 5ASAs alone at CQR entry (n=926), 5ASAs were subsequently judged to have failed in 37.8% (n=350). 5ASA failure was defined as the need for additional IBD therapies (99.1%, n=230 for IMs/biologics/small molecules and n=117 for steroids, total n=347); hospitalisation (n=3, 0.9%) or IBD surgery (n=0). Conclusion Despite not working for everyone, the long duration of 5ASA therapy indicates they are well tolerated & perceived as beneficial by consumers. There was greater 5ASA utilisation in NZ, possibly due to restricted advanced therapy access. Gender-specific trends in 5ASA administration were identified, raising the question as to why this should be so, given this is not obviously explained by disease phenotype. Further analysis is needed to tease out how such trends interact with other therapeutic access, choices and outcomes. 1 - Probert C et a. Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: rapid symptom resolution and improvements in quality of life. J Crohns Colitis. doi:10.1016/j.crohns.2013.08.007

S1092 Continuing or Discontinuing Mesalamine in Crohn's Disease? A Multinational, Propensity-Matched, Retrospective Cohort Study

Mesenteric excision surgery or conservative limited resection in Crohn’s disease: study protocol for an international, multicenter, randomized controlled trial

Corticosteroids and Mesalamine Versus Corticosteroids for Acute Severe Ulcerative Colitis: A Randomized Controlled Trial

Efficacy Of Single Vs Multiple Doses Of 5-Aminosalicylic Acid (5-Asa) In The Treatment Of Mild-Moderate Ulcerative Colitis: An Open Randomized Clinical Trial

CORTICOSTEROIDS AND 5ASA VERSUS CORTICOSTEROIDS ALONE FOR ACUTE SEVERE ULCERATIVE COLITIS: A RANDOMIZED CONTROLLED TRIAL

S36 Outcome of 5-Aminosalicylate (5-ASA) Continuation Versus Discontinuation in Patients With Inflammatory Bowel Disease Started on Biologic Therapy: A Systematic Review and Meta-analysis

Clinical study of mesalazine alone and in combination with steroids in treatment of ulcerative colitis

P1000 A meta-analysis and systematic review of 5-aminosalicylates withdrawal in Inflammatory Bowel Disease

Combination of Corticosteroids and 5-Aminosalicylates or Corticosteroids Alone for Patients with Moderate-Severe Active Ulcerative Colitis: A Global Survey of Physicians' Practice

P296 Stopping 5-Aminosalicylic Acid in Patients with Ulcerative Colitis Who Are in Clinical Remission Does Not Increase Risks of Flare

P880 The real-world use of five-aminosalicylate (5ASA) treatment for Ulcerative Colitis in Australia and New Zealand: Crohn’s Colitis Cure (CCC) data insight’s program

P846 Impact of 5-ASA discontinuation in children with ulcerative colitis under biological therapy

MMX mesalamine in ulcerative colitis: Major advantages towards classical mesalamine formulations

Continuing or stopping 5‐aminosalicylates in patients with inflammatory bowel disease on anti‐TNF therapy: A nationwide population‐based study

Combined Diosmectite and Mesalazine Treatment for Mild-to-moderate Ulcerative Colitis: a Randomized, Placebo-Controlled Study.

P312 Combination Corticosteroids With, 5-Aminosalicylic Acid Versus Corticosteroids Alone in the Treatment of Hospitalized Patients with Acute Severe Ulcerative Colitis: A Multi-Center Randomized Controlled Trial

P1054 Clinical outcomes for ulcerative colitis patients stopping 5-aminosalicylates starting biologics and/or immunomodulator therapy: A Systematic review and meta-analysis

5-Aminosalicylic Acid Chemoprevention in Inflammatory Bowel Diseases: Is It Necessary in the Age of Biologics and Small Molecules?

Standard‐dose Versus Low‐dose Azathioprine in the Treatment of Crohn's Disease: A Prospective Randomized Study

No increased risk of flare in ulcerative colitis patients in corticosteroid-free remission after stopping 5-aminosalicylic acid: A territory-wide population-based study

Stopping 5‐Aminosalicylic Acid in Ulcerative Colitis Patients in Corticosteroid‐free remission is not associated with Increased Risk of Flare: A Territory‐wide population‐based cohort study